<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698152</url>
  </required_header>
  <id_info>
    <org_study_id>ORTHO.CR.H012</org_study_id>
    <nct_id>NCT00698152</nct_id>
  </id_info>
  <brief_title>A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement</brief_title>
  <official_title>A Prospective, Non-controlled, Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this data collection is to determine long term survival rate of ArComXL®&#xD;
      highly cross-linked polyethylene&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 500 patients (cases) will be enrolled in this data collection effort and&#xD;
      10-year follow-up will be attempted. Follow-up will be obtained by sending a questionnaire&#xD;
      directly to the patients by mail. The follow-up will be annually and only survivorship data&#xD;
      will be collected.&#xD;
&#xD;
      This data collection project was developed in order to determine the actual long-term&#xD;
      (10-year) survival rate of Biomet's ArCom XL highly cross-linked polyethylene. Data will be&#xD;
      collated for uncemented cases only. This will eliminate the possibility of cement or cement&#xD;
      debris being a confounding variable.&#xD;
&#xD;
      The data gathered will be collated and used to provide feedback to designing engineers,&#xD;
      support marketing efforts, and answer potential questions from reimbursement agencies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2006</start_date>
  <completion_date type="Actual">January 15, 2016</completion_date>
  <primary_completion_date type="Actual">January 15, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of revisions and removals</measure>
    <time_frame>Annually through 10 years</time_frame>
    <description>Patient questionnaire</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">149</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ArComXL® polyethylene</arm_group_label>
    <description>ArComXL® polyethylene</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have already made the decision to undergo Total Hip Replacement and will&#xD;
        recieve ArComXL® polyethylene&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non inflammatory degenerative joint disease including osteoarthritis and avascular&#xD;
             necrosis&#xD;
&#xD;
          -  Rheumatoid Arthritis&#xD;
&#xD;
          -  Correction of Functional Deformity&#xD;
&#xD;
          -  Treatment of non-union, femoral neck fractures, trochanteric fractures of the proximal&#xD;
             femur with head involvement, unmanageable by other techniques&#xD;
&#xD;
          -  Revision of previously failed total hip arthroplasty&#xD;
&#xD;
          -  Uncemented applications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Absolute contraindications&#xD;
&#xD;
          -  Infection, sepsis and osteomyelitis&#xD;
&#xD;
        Relative contraindications&#xD;
&#xD;
          -  Uncooperative patient or patient with neurologic disorders who are incapable of&#xD;
             following directions&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Metabolic disorders which may impair bone formation&#xD;
&#xD;
          -  Osteomalacia&#xD;
&#xD;
          -  Distant foci of infections which may be spread to the implant site&#xD;
&#xD;
          -  Rapid joint destruction, marked bone loss, or bone resorption apparent on&#xD;
             roentgenogram&#xD;
&#xD;
          -  Vascular insufficiency, muscular atrophy or neuromuscular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kacy Arnold, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Orthopaedic Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic Institute of Ohio</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Valley Orthopedic and Sports Medicine</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scranton Orthopaedic Specialists, PC</name>
      <address>
        <city>Dickson City</city>
        <state>Pennsylvania</state>
        <zip>18519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Orthopedic Specialists, PA</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Hip Arthroplasty</keyword>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Hip Arthritis</keyword>
  <keyword>Polyethylene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

